Gold+
| Address | 10F Revessant, 6, Bongeunsa-ro 86-gil, Gangnam-gu, Seoul, 06163, Korea | ||
|---|---|---|---|
| Telephone | +82-10-9708-0895 | Fax | +82-2-3451-5599 |
| Website | https://www.eisaikorea.com/ | j4-hwang@eisaikorea.com | |
With its “human health care(hhc)” philosophy, Eisai remains committed to making contributions to improving people’s health throughout the world. Eisai endeavors to be a human health care company that actively in every aspect of the health of people. Eisai gives first thought to patients and their families and to increasing the benefits health care provides to them. The goal of our business activities is to provide the best health care to people around the world. With R&D centers located in North America, Europe and Asia, Eisai invests in research and development of quality medicines including ethical and over-the-counter drugs which can give hope to patients. It employs about 10,000 people in some 40 countries around the world, in including U.S. UK, Germany, China and Hong Kong who are devoted to promoting people’s health with their strong passion.
1. Differentiated Thyroid Cancer Lenvima is indicated for the treatment of patients with progressive, locally recurrent or metastatic, differentiated thyroid carcinoma (DTC), refractory to radioactive iodine (RAI). 2. Hepatocellular Carcinoma LENVIMA is indicated for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). 3. Endometrial Carcinoma LENVIMA, in combination with pembrolizumab, is indicated for the treatment of patients with advanced endometrial carcinoma who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.
HALAVEN is the only chemotherapy proven to help some women live longer when used alone after 2 prior chemotherapies for mBC in a study that included women with all types of tumor receptors. Women who received HALAVEN lived, on average, 25% longer than women who received other chemotherapy or hormone therapy.(13.2 months vs 10.6 months, respectively)
